A small molecule, Sephin1, may be able to significantly delay harm to nerve cells caused by multiple sclerosis (MS) a study has shown.
Nerve fibres are wrapped in a sheath of fatty tissue called...
Cardiorespiratory fitness has previously been associated with disease severity, walking capacity and comorbidities in people with multiple sclerosis (MS). However, current evidence is of moderate...
A recent study, which set out to retrospectively determine incidence of pregnancy, disease-modifying therapy (DMT) exposure and pregnancy outcomes in women with relapsing remitting multiple sclerosis...
Researchers who set out to analyse disability progression in secondary progressive multiple sclerosis (SPMS) patients treated with rituximab have found it can reduce disability and delay progression...
A study, published in the BMJ Journals, has revealed that people with multiple sclerosis (MS) and food allergies reported a 27% higher cumulative rate of flare-ups over the course of their disease....
In an article published in CNS Spectrums, Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat multiple...
Drug companies Alkermes and Biogen have announced that Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), an oral...
A recent study has found that multiple sclerosis (MS) patients, who are stable on interferon beta (IFNβ) therapy had better outcomes than those who chose to switch to another IFNβ.
MS patients were...
The Scottish Medicines Consortium has announce it has approved ocrelizumab (Ocrevus) for the treatment of relapsing remitting multiple sclerosis (RRMS).
The drug was approved by NICE for the...
A one-year real world study of Rebif (interferon beta 1-a) has shown that relapsing remitting multiple sclerosis (RRMS) patients experienced high treatment adherence despite seasonal weathers and...
